A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic MalignanciesPinkal Desai, James S. Blachly, Patricia Cheung et al.|Clinical Cancer Research|2024Cited by 50
P579: SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF AZD5991 IN RELAPSED/ REFRACTORY HEMATOLOGIC MALIGNANCIES: A PHASE 1 FIRST-IN-HUMAN STUDYPinkal Desai, Tapan M. Kadia, Sagar Lonial et al.|HemaSphere|2023Cited by 6
Supplementary Table S1 from A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic MalignanciesPinkal Desai, James S. Blachly, Sagar Lonial et al.|Unknown|2024Cited by 1
Data from A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic MalignanciesPinkal Desai, James S. Blachly, Sagar Lonial et al.|Unknown|2024Cited by 0
Supplementary Table S2 from A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic MalignanciesPinkal Desai, James S. Blachly, Sagar Lonial et al.|Unknown|2024Cited by 0